DC Chemicals Limited
China
Product Name: CV-6209
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Henan Tianfu Chemical Co., Ltd.
China
Product Name: 2-<propoxy>carbonyl>amino>methyl>-1-ethylpyridinium chloride
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson

100488-87-7

100488-87-7 structure

Name: CV-6209
Chemical Name: 2-carbonyl>amino>methyl>-1-ethylpyridinium chloride
CAS Number: 100488-87-7
Molecular Formula: C₃₄H₆₀ClN₃O₆
Molecular Weight: 642.31
Catalog: Research Areas Cardiovascular Disease
Create Date: 2018-06-13 18:07:12
Modify Date: 2024-01-13 23:12:52
CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats[1].

Name	2-<propoxy>carbonyl>amino>methyl>-1-ethylpyridinium chloride
Synonyms	2-{N-acetyl-N-[({2-methoxy-3-[(octadecylcarbamoyl)oxy]propoxy}carbonyl)amino]methyl}-1-ethylpyridinium chloride 2-{N-[1-(3,4-dihydroxyphenyl)ethyl]amino}acetaldehyde dimethyl acetal hydrochloride 1,2-Benzenediol,4-[1-[(2,2-dimethoxyethyl)amino]ethyl]-,hydrochloride 2-(2-ACETYL-6-METHOXY-3,9-DIOXO-4,8-DIOXA-2,10-DIAZAOCTACOS-1-YL)-1-ETHYL-PYRIDINIUM CHLORIDE

Description	CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
Target	platelet activating factor (PAF)[1]
In Vitro	CV-6209 inhibits [3H]serotonin release from rabbit platelets stimulated with PAF (30 nM)[1]. CV-6209 has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen[1]. CV-6209 (0.2-2 μM; pretreated for 30 min) inhibits PAF-induced MC degranulation in both LAD2 and hLMCs[1].
In Vivo	CV-6209 (i.v.) inhibits PAF (0.3 μg/kg; i.v.)-induced hypotension in rats (ED50=0.009 mg/kg) with no effect on the hypotension induced by arachidonic acid, histamine, bradykinin and isoproterenol[1]. CV-6209 (66 μg; i.v.) reduces asparaginase-induced hypersensitivity compared with nonpretreated, sensitized mice[3].
References	[1]. Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8. [2]. Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017;27(3):161-168. [3]. Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352(3):541-51.